Abstract

Sildenafil 2.5 mg/mL in Methylcellulose 1%:Syrup (1:1) Oral Suspension

Author(s): Allen Loyd V Jr

Issue: May/Jun 2020 - Volume 24, Number 3

Page(s): 230

Download in electronic PDF format for $75
  • Sildenafil 2.5 mg/mL in Methylcellulose 1%:Syrup (1:1) Oral Suspension Page 1

Abstract

A formulation for preparing Sildenafil 2.5 mg/mL in Methylcellulose 1%:Syrup (1:1) Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • sildenafil
  • formulation
  • impotence
  • erectile dysfunction
  • penis
  • phosphodiesterase type 5 inhibitor
  • smooth muscle relaxation
  • corpus cavernosum

Related Categories

  • FORMULATIONS
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2020
Pg. 230
Sildenafil 2.5 mg/mL in Methylcellulose 1%:Syrup (1:1) Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2006
Pg. 306
Sildenafil Citrate 2.5-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
May/Jun 2019
Pg. 236
Sildenafil 2.5 mg/mL in Ora-Plus:Ora-Sweet
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
Jan/Feb 2021
Pg. 18-23
Reversing Erectile Dysfunction and Urinary Incontinence After Prostatectomy or Radiotherapy: The Stanley Prostate-Cancer Treatment Protocol
Author(s): McKettrick Greg, Yoch Doug
Mar/Apr 2007
Pg. 122-124
Compounded Treatments for Erectile Dysfunction: A Common Complication of Diabetes
Author(s): Fields Shannon W
Jan/Feb 2021
Pg. 82-87
Physical-chemical Stability of Compounded Sildenafil 100-mg Rapid-dissolving Tablets
Author(s): Cheung Matthew, Zhao Fang, Dave Vivek S
May/Jun 2019
Pg. 230
Aripiprazole 1 mg/mL in Methylcellulose 1% Syrup Oral Suspension
Author(s): Allen Loyd V Jr
May/Jun 2016
Pg. 247-249
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Author(s): Nahata Milap C
Jan/Feb 2013
Pg. 24-27
Treatment of Canine Pulmonary Hypertension: Is Tadalafil an Appropriate Alternative to Sildenafil?
Author(s): Wung Deanna
Nov/Dec 2006
Pg. 405-408
Application of Sildenafil for Pulmonary Hypertension in Canines and Foals
Author(s): Davidson Gigi S
Sep/Oct 2021
Pg. 372-377
Compounding Pearls--Wound Care: Drugs and Formulations for Dermal Healing, Part 3: The Roles of Nitric Oxide, Sildenafil, and Naltrexone
Author(s): Riepl Mike
Mar/Apr 2021
Pg. 94-98
The Stanley Prostate-cancer Treatment Protocol for Erectile Dysfunction After Prostatectomy and/or Radiotherapy: A Case Report
Author(s): McKettrick Greg, Yoch Doug
Mar/Apr 2010
Pg. 105-107
Determining the Causes of Erectile Dysfunction: Can Medications Be a Double-Sided Sword?
Author(s): Williams LaVonn A
May/Jun 2004
Pg. 231-235
Long-Term Stability of Trimix: A Three-Drug Injection Used to Treat Erectile Dysfunction.
Author(s): Trissel Lawrence A, Zhang Yanping
Nov/Dec 2019
Pg. 492
Tadalafil 5 mg/mL in Oral-Plus:Ora-Sweet (1:1)
Author(s): Allen Loyd V Jr
Jan/Feb 2020
Pg. 56
Glycopyrrolate 0.2 mg/mL in Methylcellulose 1% and Syrup
Author(s): Allen Loyd V Jr
Jan/Feb 2021
Pg. 45
Cyclophosphamide 10 mg/mL in Oral-Plus or Simple Syrup Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2003
Pg. 473
Perphenazine 2.5-mg/5-mL Syrup
Author(s): Allen Loyd V Jr